OncoCyte (STU:7OC0) Dividend Payout Ratio : 0.00 (As of Dec. 2023)

View and export this data going back to 2018. Start your Free Trial

OncoCyte's dividend payout ratio for the months ended in Dec. 2023 was 0.00.

The historical rank and industry rank for OncoCyte's Dividend Payout Ratio or its related term are showing as below:

STU:7OC0's Dividend Payout Ratio is not ranked ^*
in the Medical Diagnostics & Research industry.
Industry Median: 0.41
* Ranked among companies with meaningful Dividend Payout Ratio only.

As of today (2024-04-24), the Dividend Yield % of OncoCyte is 0.00%.

OncoCyte's Dividends per Share for the months ended in Dec. 2023 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.

OncoCyte Dividend Payout Ratio Historical Data

The historical data trend for OncoCyte's Dividend Payout Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoCyte Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dividend Payout Ratio

Get a 7-Day Free Trial

OncoCyte Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Dividend Payout Ratio	Get a 7-Day Free Trial															-	-	-	-	-

Competitive Comparison

For the Diagnostics & Research subindustry, OncoCyte's Dividend Payout Ratio, along with its competitors' market caps and Dividend Payout Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

OncoCyte Dividend Payout Ratio Distribution

For the Medical Diagnostics & Research industry and Healthcare sector, OncoCyte's Dividend Payout Ratio distribution charts can be found below:

* The bar in red indicates where OncoCyte's Dividend Payout Ratio falls into.

OncoCyte Dividend Payout Ratio Calculation

Dividend payout ratio measures the percentage of the company's earnings paid out as dividends.

OncoCyte's Dividend Payout Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (A: Dec. 2023 )	/	EPS without NRI (A: Dec. 2023 )
	=	0	/	-2.757
	=	N/A

OncoCyte's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio	=	Dividends per Share (Q: Dec. 2023 )	/	EPS without NRI (Q: Dec. 2023 )
	=	0	/	-0.757
	=	N/A

OncoCyte (STU:7OC0) Dividend Payout Ratio Explanation

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

OncoCyte Dividend Payout Ratio Related Terms

Thank you for viewing the detailed overview of OncoCyte's Dividend Payout Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.

OncoCyte (STU:7OC0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » OncoCyte Corp (STU:7OC0) » Definitions » Dividend Payout Ratio

Comparable Companies

Traded in Other Exchanges

OCX:USA

Address

15 Cushing, Irvine, CA, USA, 92618

Website

https://www.oncocyte.com

OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States.

OncoCyte (STU:7OC0) Headlines

No Headlines